natgillin/translations-raw huggingface dataset:
During the reporting period, one (1) case report which concerned a 71 year-old male patient with myelodysplastic syndromes (MDS), who developed progressive erythematous, blistering rash with pustular component on the trunk four (4) weeks after commencing Exjade therapy, has been identified in the literature.
V obdobju poročanja so v literaturi odkrili en (1) opis primera, ki se je nanašal na 71-letnega bolnika z mielodisplastičnimi sindromom (MDS), pri katerem je štiri (4) tedne po začetku zdravljenja z zdravilom Exjade prišlo do progresivnega eritematemskega mehurčastega izpuščaja s pustuloznimi spremembami po trupu.
During the second cycle when all medicinal products were administered on the same day, the most common infusion reactions in the Perjeta-treated group (≥ 1.0%) were fatigue, dysgeusia, drug hypersensitivity, myalgia and vomiting (see section 4.4).
V drugem ciklusu, ko so bila vsa zdravila uporabljena isti dan, so bile najpogostejše infuzijske reakcije (≥ 1,0 %) v skupini, ki je prejemala zdravilo Perjeta, utrujenost, sprememba okusa v ustih, preobčutljivost na zdravilo, bolečina v mišicah in bruhanje (glejte poglavje 4.4).
During the second week of treatment, the dose can be increased to 18 mg per day or decreased to 4.5 mg per day.
Drugi teden zdravljenja se odmerek lahko poveča na 18 mg na dan ali zmanjša na 4,5 mg na dan.
During the second week, the patient takes Leganto 4 mg/24 h.
V drugem tednu uporablja zdravilo Leganto 4 mg/24 h.
During the second week, the patient takes Neupro 4 mg/24 h.
V drugem tednu uporablja zdravilo Neupro 4 mg/24 h.
During the shelf life, the patient may store the capsules for a single period of 2 months at a temperature not above 25°C, after which the medicinal product must be discarded.
Med rokom uporabnosti lahko bolnik shranjuje kapsule pri temperaturi do 25 °C le 2 meseca, potem pa jih mora zavreči.
During the shelf-life, the product may be kept at room temperature (up to 25°C) for a single period not exceeding 1 month.
V času do izteka roka uporabnosti je zdravilo lahko shranjeno pri sobni temperaturi (do 25°C) za enkratno obdobje, ki ni daljše od 1 meseca.
During the shelf-life, the product may be kept at room temperature ≤30°C for a single period not exceeding 6 months.
V času do izteka roka uporabnosti je zdravilo lahko shranjeno pri sobni temperaturi (≤ 30 °C) za enkratno obdobje, ki ni daljše od 9 mesecev.
During the Simponi Phase IIb and Phase III clinical trials in RA, PsA and AS, the incidence of lymphoma in Simponi-treated patients was higher than expected in the general population.
V kliničnih preskušanjih faze IIb in faze III z zdravilom Simponi pri bolnikih z RA, PsA in AS je bila incidenca limfoma pri bolnikih, zdravljenih z zdravilom Simponi, večja od njegove pričakovane incidence za splošno populacijo.
During the studies, mortality was lower in the epoetin theta group (6.9%) compared to placebo (10.3%).
Med temi študijami je bila umrljivost manjša v skupini, ki je prejemala epoetin theta, (6,9-odstotna) kot v skupini, ki je prejemala placebo (10,3-odstotna).
During the studies, the most common side effects with Evra (seen in more than 1 patient in 10) were headache, nausea (feeling sick) and breast tenderness.
Najpogostejši neželeni učinki (opaženi pri več kot 1 uporabnici od 10), ki so jih zabeležili med študijami, so bili glavobol, slabost in občutljivost v prsih.
During the study, low-dose folic acid and vitamin B12 supplementation was introduced to patients’ therapy to reduce toxicity.
Med študijo so bolnikom uvedli v terapijo nizke odmerke dopolnilne folne kisline in vitamin B12, za zmanjšanje toksičnosti.
During the study, low-dose folic acid and vitamin B12 supplementation was introduced to patients’ therapy to reduce toxicity.
V trajanju študije so bolnikom uvedli v terapijo nizke odmerke dopolnilne folne kisline in vitamina B12, za zmanjšanje toksičnosti.
During the third week,
Tretji teden zdravljenja pa se odmerek lahko
During the third week, he or she takes Leganto 6 mg/24 h and during the fourth week Leganto 8 mg/24 h.
Tretji teden uporablja zdravilo Leganto 6 mg/24 h, četrti teden pa zdravilo Leganto 8 mg/24 h.
During the third week, he or she takes Neupro 6 mg/24 h and during the fourth week Neupro 8 mg/24 h.
Tretji teden uporablja zdravilo Neupro 6 mg/24 h, četrti teden pa zdravilo Neupro 8 mg/24 h.
During the third year of life, there were no cases of severe RV gastro-enteritis in the Rotarix group (N=4,222) versus 13 (0.3%) in the placebo group (N=4,185).
V tretjem letu življenja med prejemniki cepiva Rotarix (n = 4.222) ni bilo primerov hudega RV gastroenteritisa, med prejemniki placeba (n = 4.185) pa jih je bilo 13 (0,3 %).
During the time period of declining efavirenz plasma levels and increasing rilpivirine plasma levels after switching, none of the patients had efavirenz or rilpivirine levels below their respective IC90 levels at the same time.
V obdobju upadanja ravni efavirenza v plazmi in povečevanja ravni rilpivirina v plazmi po prehodu ni imel noben bolnik ravni efavirenza ali rilpivirina pod ravnmi IC90 sočasno.
During the treatment course with Herceptin subcutaneous formulation in administration system, other medicinal products for subcutaneous administration should preferably be injected at different sites.
Med zdravljenjem s subkutano obliko zdravila Herceptin v aplikacijskem sistemu je treba druga zdravila, ki se prav tako dajejo subkutano, injicirati na druga mesta.
During the treatment period (induction treatment phase comprising of R-CHOP for at most eight cycles), four patients (2 %) treated with R-CHOP, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle.
Med obdobjem zdravljenja (faza indukcijskega zdravljenja, ki je obsegalo R-CHOP vsaj osem ciklov) so se pri štirih bolnikih (2 %), zdravljenih z R-CHOP, ki so vsi imeli kardiovaskularne dejavnike tveganja, med prvim ciklom zdravljenja pojavili trombembolični cerebrovaskularni dogodki.
During the treatment period, 83% of patients received luteinising hormone-releasing hormone (LHRH) agonists and 26% of patients received anti-androgens concomitantly.
V obdobju zdravljenja je 83 % bolnikov sočasno prejemalo agoniste luteinizirajoči hormon sproščajočega hormona (LHRH) in 26 % bolnikov antiandrogena zdravila.
During the treatment period, rare clinical effects (> 0.01% to < 0.1%) have been reported: hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence, down-regulation associated signs (decrease in testicle size, reduced activity).
Med obdobjem učinkovanja zdravila je prišlo do redkih kliničnih učinkov (> 0,01% do < 0,1%), podobnih tistim, med drugim zdravja motenj dlake (npr. izgube dlake, alopecije, spremembe dlake), uhajanja seča, zmanjšanja povezanih znakov (npr. zmanjšanje velikosti mod, zmanjšana aktivnost).
During the treatment period, rare clinical effects (> 0.01% to < 0.1%) have been reported: hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence, down-regulation associated signs (e.g. decrease in testicle size, reduced activity).
Med obdobjem učinkovanja zdravila je prišlo do redkih kliničnih učinkov (> 0,01% do < 0,1%), podobnih tistim med drugim zdravja motenj dlake (npr. izgube dlake, alopecije, spremembe dlake), uhajanja seča, zmanjšanja povezanih znakov (npr. zmanjšanje velikosti mod, zmanjšana aktivnost).
During the treatment period, your doctor will carefully monitor you and decide the most appropriate dosage of Yondelis to give to you.
V času zdravljenja vas bo zdravnik skrbno nadziral in določil najbolj ustrezni odmerek zdravila Yondelis za vas.
During the treatment with Sebivo:
V času jemanja zdravila Sebivo:
During the treatment with Thalidomide Celgene you have an increased risk of developing blood clots in the veins and arteries.
Med zdravljenjem z zdravilom Thalidomide Celgene je tveganje za nastanek krvnih strdkov v venah in arterijah povečano;
During the treatment:
Med zdravljenjem:
During the urine storage phase, when urine accumulates in the bladder, sympathetic nerve stimulation predominates.
Med fazo shranjevanja urina, ko se urin nabira v mehurju, prevladuje simpatična ţivčna stimulacija.
During the urine voiding phase, the bladder is predominantly under parasympathetic nervous system control.
Med fazo praznjenja urina je mehur preteţno pod nadzorom parasimpatičnega ţivčevja.
During the withdrawal period, symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months.
Med odtegnitvenim obdobjem so se simptomi psoriaze postopoma znova pojavili; mediani čas do recidiva bolezni je bil 3 mesece.
During the withdrawal phase (Part II), the percentage of patients achieving JIA ACR 30, 50, and 70 responses at Week 40 relative to baseline are shown in Table 8.
V preglednici 8 so prikazani deleži bolnikov, ki so med fazo odtegnitve (II. del) po 40 tednih dosegli odzive JIA ACR 30, 50 in 70 glede na izhodiščno vrednost.
During the ‘induction’ phase, Vistide is given as a one-hour infusion of 5 mg per kilogram body weight once a week for the first two weeks.
Med obdobjem uvajanja se zdravilo Vistide prva dva tedna daje enkrat tedensko kot eno uro trajajoča infuzija v odmerku 5 mg na kilogram telesne mase.
During therapy patient’s weight should be monitored.
Med zdravljenjem moramo spremljati bolnikovo telesno maso.
During therapy patient’s weight should be monitored.
Med zdravljenjem moramo zato spremljati bolnikovo telesno maso.
During therapy with eltrombopag full blood counts (FBCs), including platelet count and peripheral blood smears, should be assessed weekly until a stable platelet count (≥ 50,000/µl for at least 4 weeks) has been achieved.
Med zdravljenjem z eltrombopagom je treba tedensko opravljati preiskave celotne krvne slike, vključno s številom trombocitov in razmazi periferne krvi, dokler ni doseženo stabilno število trombocitov (≥ 50.000/µl za najmanj 4 tedne).
During therapy, monthly monitoring of ALT and AST is recommended.
Med zdravljenjem je priporočljivo mesečno nadzirati vrednosti ALT in AST.
During these two phase III studies, the safety profile of docetaxel was consistent with the safety profile observed in phase II studies (see section 4.8).
Med študijama III. faze se je varnostni profil docetaksela skladal z varnostnim profilom, ugotovljenim v študijah II. faze (glejte poglavje 4.8).
During this period when you have stored MIRCERA at a room temperature not above 30 C you may not put MIRCERA back in the refrigerator before use.
V tem času, ko ste svoje zdravilo hranili pri sobni temperaturi do 30 °C, pred uporabo zdravila ne smete vrniti nazaj v hladilnik.
During this period, concentrations of skatole and androstenone were below the threshold levels associated with the risk of boar taint.
Med tem obdobjem so bile koncentracije skatola in androstenona pod pragom, povezanim s tveganjem vonja po merjascu.
During this period, patients should wear dark sunglasses, which have an average white light transmittance of < 4% when outdoors.
V tem času morajo bolniki nositi temna očala s povprečno prepustnostjo bele svetlobe <4% na prostem.
During this period, the patient should be carefully monitored for any signs or symptoms of a sudden decrease in blood pressure or heart rate.
V tem obdobju je treba pri bolnikih skrbno spremljati morebiten pojav kakršnih koli znakov ali simptomov nenadnega znižanja krvnega tlaka ali srčnega utripa.
During this priming process product will be expelled.
Pri tem postopku priprave pršila se bo razpršilo nekaj zdravila.
During this time the liposomes are formed spontaneously (Figure 2).
V tem času samodejno nastajajo liposomi (slika 2).
During this time, female patients of childbearing potential should use two effective non-hormonal methods of contraception.
V tem času morajo bolnice v rodni dobi uporabljati dve učinkoviti ne-hormonski kontracepcijski metodi.
During this time, postpartum patients should follow the same dose recommendation as for non- pregnant patients, including those for co-administration of medicinal products known to affect atazanavir exposure (see section 4.5).
V tem obdobju je treba za bolnice upoštevati priporočeno odmerjanje za ne-noseče bolnice, vključno s priporočili glede sočasne uporabe zdravil, za katera je znano, da vplivajo na izpostavljenost atazanavirju (glejte poglavje 4.5).
During this time, you will have to follow your doctor’s instructions and keep your eyes still.
V tem času se boste morali ravnati po zdravnikovih navodilih in ne boste smeli premikati oči.
During this week you are protected from getting pregnant only if you start your next patch on time.
V tem tednu ste zaščiteni pred nosečnostjo, le če nov obliž uporabite pravočasno.
During titration, if adequate analgesia is not obtained within 30 minutes after the start of administration of a single tablet, a second Effentora tablet of the same strength may be used.
Če se med titriranjem ustrezen analgetični učinek ne doseže v 30 minutah po začetku apliciranja ene tablete, se lahko uporabi druga tableta zdravila Effentora enake jakosti.
During titration, multiple tablets may be used: up to four 100 micrograms or up to four 200 micrograms tablets may be used to treat a single episode of BTP during dose titration according to the following schedule:
Med titriranjem je možno uporabiti več tablet: do štiri 100-mikrogramske ali do štiri 200- mikrogramske tablete se lahko uporabijo za zdravljenje ene epizode PBB med titriranjem odmerka po naslednjem režimu:
During titration, patients should be monitored for serum sodium and volume status (see section 4.4).
Med titriranjem je treba pri bolnikih nadzirati natrij v serumu in stanje volumna (glejte poglavje 4.4).
During transient illnesses such as low grade infection, fever of any aetiology, stressful situations such as minor surgical procedures, the daily replacement dose must be increased temporarily, see section 4.2, ‘Use in intercurrent illness’.
Med prehodnimi boleznimi, kot so blage okužbe, zvišana telesna temperatura katerekoli etiologije, naporne situacije, kot so manjši kirurški posegi, je treba dnevni nadomestni odmerek začasno povečati; glejte poglavje 4.2 „Uporaba pri sočasni bolezni“.
During treatment (including dose interruptions), every 4 weeks except in case of confirmed tubal sterilisation
med zdravljenjem (vključno s prekinitvami odmerjanja) vsake 4 tedne, razen v primeru potrjene sterilizacije jajcevodov,
During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose of TMZ).
22. dan zdravljenja (21 dni po prvem odmerku temozolomida) je treba narediti celotno krvno sliko.
During treatment all animals must have solely but unrestricted access to the medicated water.
Med zdravljenjem morajo imeti v se živali dostop samo do medicirane vode, ki pa mora biti neomejen.
During treatment and during the 20 months after your treatment has finished, tell your doctor straight away if:
Zdravnika morate takoj obvestiti, če se v času zdravljenja in še 20 mesecev po zaključku zdravljenja zgodi kaj od naslednjega:
During treatment based on method of contraception
med zdravljenjem, glede na kontracepcijsko metodo,
during treatment for 1 week after stopping treatment
med zdravljenjem še 1 teden po koncu zdravljenja
During treatment of VTE, concomitant therapy with vitamin K antagonist should be administered in accordance with the information of Section 4.5. Other antiplatelet medicinal products (acetylsalicylic acid, dipyridamole, sulfinpyrazone, ticlopidine or clopidogrel), and NSAIDs should be used with caution.
Med zdravljenjem VTE je potrebno sočasno zdravljenje z antagonistom vitamina K v skladu s podatki v poglavju 4.5. Druga antitrombotična zdravila (acetilsalicilna kislina, dipiridamol, sulfinpirazon, tiklopidin ali klopidogrel) in NSAID moramo uporabljati previdno.
During treatment period
Med zdravljenjem
during treatment until 4 weeks after stopping treatment
4 tedne po koncu zdravljenja
During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.
Med zdravljenjem živali z zdravilom Advocate, ne nanašajte drugih antiparazitikov iz skupine makrocikličnih laktonov.
During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered.
Pri zdravljenju z zdravilom Advocate odsvetujemo sočasno uporabo drugih antiparazitikov iz skupine makrocikličnih laktonov.
During treatment with Atosiban SUN, your contractions and your unborn baby’s heart rate may be monitored.
Med zdravljenjem z zdravilom Atosiban SUN bodo po potrebi nadzirali kontrakcije vaše maternice in srčno frekvenco ploda.
During treatment with Betaferon your body may produce substances called neutralising antibodies, which may react with Betaferon (neutralising activity).
Med zdravljenjem z zdravilom Betaferon lahko vaše telo izdela snovi, imenovane nevtralizacijska protitelesa, ki lahko reagirajo z zdravilom Betaferon (nevtralizacija).
During treatment with Betaferon, kidney problems that may reduce your kidney function, including scarring (glomerulosclerosis), may occur.
Med zdravljenjem z zdravilom Betaferon, se lahko pojavijo težave z ledvicami, ki poslabšajo delovanje ledvic, tudi brazgotinjenje (glomeruloskleroza).
During treatment with Cinacalcet Mylan, tell your doctor: if you start or stop smoking, as this may affect the way Cinacalcet Mylan works.
Med zdravljenjem z zdravilom Cinakalcet Mylan morate zdravniku povedati: če začnete ali prenehate kaditi, kajti to lahko vpliva na delovanje zdravila Cinakalcet Mylan.
During treatment with Ebilfumin, tell a doctor immediately: if you notice changes in behaviour or mood (neuropsychiatric events), especially in children and adolescents.
Med zdravljenjem z zdravilom Ebilfumin morate nemudoma povedati svojemu zdravniku: če ste opazili spremembe v obnašanju ali razpoloženju (nevropsihiatrični dogodki), še posebej pri otrocih in mladostnikih.
During treatment with Efficib, your doctor will check your kidney function at least once a year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening
Med zdravljenjem z zdravilom Efficib vam bo zdravnik preveril delovanje ledvic vsaj enkrat na leto ali pogosteje, če ste starejši ali če je delovanje vaših ledvic na meji normalnega ali če obstaja tveganje za poslabšanje.
During treatment with Efficib, your doctor will check your kidney function at least once a year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening.
Med zdravljenjem z zdravilom Efficib vam bo zdravnik preveril delovanje ledvic vsaj enkrat na leto ali pogosteje, če ste starejši ali če je delovanje vaših ledvic na meji normalnega ali če obstaja tveganje za poslabšanje.
During treatment with Emselex, tell your doctor straight away and stop taking Emselex if you experience swelling of the face, lips, tongue and/or throat (signs of angioedema).
Če se tekom zdravljenja pojavijo otekanje obraza, ustnic, jezika in/ali grla (znaki angioedema), takoj obvestite svojega zdravnika in prekinite jemanje zdravila Emselex.
During treatment with Enurev Breezhaler, stop taking this medicine and tell your doctor immediately: if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Enurev Breezhaler (signs of bronchospasm).
Med zdravljenjem z zdravilom Enurev Breezhaler, takoj prenehajte uporabljati to zdravilo in obvestite zdravnika: če vas začne takoj po uporabi zdravila Enurev Breezhaler stiskati v prsih, če začnete kašljati, če vam v pljučih piska ali vam zmanjkuje sape (to so znaki bronhospazma),
During treatment with Extavia your body may produce substances called neutralising antibodies, which may react with Extavia.
Med zdravljenjem z zdravilom Extavia lahko vaše telo proizvede snovi, imenovane nevtralizirajoča protitelesa, ki lahko reagirajo z zdravilom Extavia.
During treatment with Extavia, kidney problems that may reduce your kidney function, including scarring (glomerulosclerosis), may occur.
Med zdravljenjem z zdravilom Extavia lahko pride do težav z ledvicami, ki lahko zmanjšajo delovanje ledvic, med drugim do brazgotinjenja (glomeruloskleroze).
During treatment with Hirobriz Breezhaler,
Med zdravljenjem z zdravilom Hirobriz Breezhaler
During treatment with immunosuppressants, including Rapamune, vaccination may be less effective.
Med zdravljenjem z imunosupresivi, tudi z zdravilom Rapamune, je lahko učinkovitost cepiva zmanjšana.
During treatment with Janumet, your doctor will check your kidney function at least once a year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening
Med zdravljenjem z zdravilom Janumet vam bo zdravnik preveril delovanje ledvic vsaj enkrat na leto ali pogosteje, če ste starejši ali če je delovanje vaših ledvic na meji normalnega ali če obstaja tveganje za poslabšanje.
During treatment with Komboglyze:
Med zdravljenjem s tem zdravilom:
During treatment with Lamivudine Teva patients should be monitored regularly.
Med zdravljenjem z zdravilom Lamivudin Teva je treba bolnike redno nadzirati.
During treatment with Mimpara, tell your doctor: if you start or stop smoking, as this may affect the way Mimpara works.
Med zdravljenjem z zdravilom Mimpara morate svojemu zdravniku povedati: če začnete ali prenehate kaditi, kajti to lahko vpliva na delovanje zdravila Mimpara.
During treatment with NeoRecormon
Med zdravljenjem z zdravilom NeoRecormon
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali divalproeksom se je pri 17,4 % bolnikov med akutnim zdravljenjem (do 6 tednov) pojavilo povečanje telesne mase za > 7 % od osnovne.
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali divalproeksom se je pri 17,4 % bolnikov med akutnim zdravljenjem ( do 6 tednov) pojavilo povečanje telesne mase za > 7 % z osnove.
During treatment with Onbrez Breezhaler,
Med zdravljenjem z zdravilom Onbrez Breezhaler
During treatment with Oslif Breezhaler,
Med zdravljenjem z zdravilom Oslif Breezhaler
During treatment with pixantrone, you should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment).
Med zdravljenjem s piksantronom morate zmanjšati ali se izogibati izpostavljenosti naravni ali umetni sončni svetlobi (solariji ali zdravljenje z žarki UVA/B).
During treatment with Remicade
Med zdravljenjem s tem zdravilom
During treatment with Remsima
Med zdravljenjem s tem zdravilom
During treatment with Retacrit
Med zdravljenjem z zdravilom Retacrit
During treatment with Ribavirin Teva Pharma B.V. in combination therapy with an alpha interferon, patients may experience eye problems, or loss of vision in rare instances.
Med zdravljenjem s kombinacijo zdravila Ribavirin Teva Pharma B.V. z interferonom alfa imajo bolniki lahko težave z očmi, ali v redkih primerih izgubijo vid.
During treatment with Ristfor, your doctor will check your kidney function at least once a year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening
Med zdravljenjem z zdravilom Ristfor vam bo zdravnik preveril delovanje ledvic vsaj enkrat na leto ali pogosteje, če ste starejši ali če je delovanje vaših ledvic na meji normalnega ali če obstaja tveganje za poslabšanje.
During treatment with Savene the area where the extravasation has occurred will be examined on a regular basis and you will have blood tests taken regularly to check your blood cells.
Med zdravljenjem z zdravilom Savene vam bodo redno pregledovali območje ekstravazacije in opravljali preiskave krvi, da bodo preverjali celice v krvi.